ACTRN12616001423404
Completed
Phase 4
Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum in Democratic Republic of Congo
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Malaria
- Sponsor
- Ministry of Health
- Enrollment
- 534
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. age between six to 59 months;
- •2\. mono\-infection with P. falciparum detected by microscopy;
- •3\. parasitaemia of 2000–200,000/microliter asexual forms;
- •4\. presence of axillary temperature greater or equal to 37\.5 degrees C or history of fever during the past 24 h
- •5\. ability to swallow oral medication;
- •6\. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7\. informed consent from the parent or guardian.
Exclusion Criteria
- •1\. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
- •2\. weight under 5 kg;
- •3\. Haemoglobin \< 8g/dl;
- •4\. mixed or mono\-infection with another Plasmodium species detected by microscopy;
- •5\. presence of severe malnutrition defined as a child aged 6\-60 months has a mid\-upper arm circumference belo 115 mm)
- •6\. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •7\. regular medication, which may interfere with antimalarial pharmacokinetics;
- •8\. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A study on siddha medicine kumaara veeriya kaantha chenduram for anaemiaHealth Condition 1: D508- Other iron deficiency anemiasCTRI/2019/04/018795Ayothidoss Pandithar hospital30
Not yet recruiting
Phase 2
Evaluation of safety and therapeutic efficacy of siddha drug KANDAAMALAGA ILAKAM in the treatment of Iron deficiency anaemia.Health Condition 1: null- patients complaints with pallor of skin and mucus membrane, fatigue, lassitude,chest discomfort, breathlessness,pica,giddiness,dizziness,angular stomatitis, pungent or bitter taste.CTRI/2018/05/014111Ayothidoss Pandithar Hospital
Active, not recruiting
Phase 1
Study of the safety and effectiveness of drug AZD4017 at reducing pressure in the brain, in idiopathic intracranial hypertension.Idiopathic Intracranial HypertensionMedDRA version: 18.0Level: PTClassification code 10004277Term: Benign intracranial hypertensionSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-003643-31-GBniversity of Birmingham30
Not yet recruiting
Phase 2
VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000298ational Center of Bioproducts (BioCen)180
Active, not recruiting
Phase 1
Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: Therapeutic potential of adipose-derived stem cells, proven in clinical trials and examined in vitro - rationale for banking of well characterized cells”Diabetic foot ulcerMedDRA version: 20.0 Level: LLT Classification code 10012664 Term: Diabetic foot ulcer System Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-004109-15-PLMedical University of Warsaw50